Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers

References

• Chobanian AV Bakris GL Black HR National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 2003 289 19 2560 2572 12748199
   PubMed Web of Science ®Google Scholar
• Meka N Katragadda S Cherian B Arora RR Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers Am J Ther 2010 17 1 61 67 20090431
   PubMed Web of Science ®Google Scholar
• Kim-Mitsuyama S Ogawa H Matsui K Jinnouchi T Jinnouchi H Arakawa K An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone Kidney Int 2013 83 1 167 176 23051740
   PubMed Web of Science ®Google Scholar
• Woo KT Wong KS Choong HL Foo MW Tan HK Chan CM Angiotensin receptor blocker and calcium channel blocker combination prevents cardiovascular events in CKD better than high-dose ARB alone Kidney Int 2013 84 1 214 215 23812366
   PubMed Web of Science ®Google Scholar
• Mori H Ukai H Yamamoto H Current status of antihypertensive prescription and associated blood pressure control in Japan Hypertens Res 2006 29 3 143 151 16755149
   PubMed Web of Science ®Google Scholar
• Brachmann J Ansari A Mahla G Handrock R Klebs S Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy Adv Ther 2008 25 5 399 411 18465097
   PubMed Web of Science ®Google Scholar
• Minami J Kawano Y Makino Y Matsuoka H Takishita S Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension Br J Clin Pharmacol 2000 50 6 615 620 11136301
   PubMed Web of Science ®Google Scholar
• Kario K Nariyama J Kido H Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients J Clin Hypertens (Greenwich) 2013 15 7 465 472 23815534
   PubMed Web of Science ®Google Scholar
• Minami J Ishimitsu T Kawano Y Numabe A Matsuoka H Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard J Cardiovasc Pharmacol 1998 32 2 331 336 9700998
   PubMed Web of Science ®Google Scholar
• Mistry NB Westheim AS Kjeldsen SE The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials Expert Opin Pharmacother 2006 7 5 575 581 16553573
   PubMed Web of Science ®Google Scholar
• Biswas PN Wilton LV Shakir SW The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England J Hum Hypertens 2002 16 11 795 803 12444541
   PubMed Web of Science ®Google Scholar
• Williams JR Revising the Declaration of Helsinki World Med J 2008 54 120 122
   Google Scholar
• Markham A Goa KL Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Drugs 1997 54 2 299 311 9257084
   PubMed Web of Science ®Google Scholar
• Kanaoka T Tamura K Wakui H L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease Int J Mol Sci 2013 14 8 16866 16881 23959116
   PubMed Web of Science ®Google Scholar
• Liu XQ Zhao Y Li D Qian ZY Wang GJ Metabolism and metabolic inhibition of cilnidipine in human liver microsomes Acta Pharmacol Sin 2003 24 3 263 268 12617777
   PubMed Web of Science ®Google Scholar
• Poirier A Cascais AC Funk C Lavé T Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data Chem Biodivers 2009 6 11 1975 1987 19937834
   PubMed Web of Science ®Google Scholar
• Julius S Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation Cardiology 1999 91 Suppl 1 S8 S13
   Web of Science ®Google Scholar
• Csajka C Buclin T Fattinger K Brunner HR Biollaz J Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers Clin Pharmacokinet 2002 41 2 137 152 11888333
   PubMed Web of Science ®Google Scholar
• Tanigawara Y Yoshihara K Kuramoto K Arakawa K Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis Drug Metab Pharmacokinet 2009 24 4 376 388 19745564
   PubMed Web of Science ®Google Scholar
• Lee J Han S Jeon S Hong T Yim DS Pharmacokinetic-pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects Eur J Clin Pharmacol 2013 69 1 11 20 22660441
   PubMed Web of Science ®Google Scholar
• Takahara A Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release Cardiovasc Ther 2009 27 2 124 139 19426250
   PubMed Web of Science ®Google Scholar
• Philips B Somer V American Pharmaceutical Association Drug Information Handbook for Cardiology Hudson, OH Lexi-Comp 2000
   Google Scholar
• Kondrack R Mohiuddin S Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy Expert Opin Drug Metab Toxicol 2009 5 9 1125 1134 19689218
   PubMed Web of Science ®Google Scholar
• Lee H Kim KS Chae SC Jeong MH Kim DS Oh BH Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension Clin Ther 2013 35 9 1337 1349 23932463
   PubMed Web of Science ®Google Scholar